Upgrade to premium to see the full reasoning behind each conviction change.
Sign in to unlockFair Value Distribution — percentile bands
100.0% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
-7.2%/yr
±3.5% · revenue growth to justify current price
FCF-Based Reverse DCF
7.8%/yr
±3.0% · FCF growth to justify current price
THE GAP
Market pricing margin compression or rising capex
Upgrade to premium for full distribution data, sensitivity analysis, and segment breakdowns.
Sign in to unlockConv 8. KKR partnership = named catalyst (>$200M operating income improvement). DCF P(above)=92.2%, FV=$145 vs $74 = 95% upside (exceptional). Dental/medical specialty mix with demographic tailwind (45+ population +10% through 2035). Above 200dma.
MACD negative (-0.72), RSI 39 trending down, 5-day momentum -1.9%. Below 50dma despite being above 200dma. Partner integration risk with KKR.
KKR partnership falls through, dental market consolidation disrupts distribution economics, GPO pricing pressure
Updated Mar 18
Henry Schein Q4 FY2025: total net sales +7.7% YoY with Global Specialty Products up 14.6%, signaling post-cyberattack recovery strengthening. Contrarian flag: short interest up 28.9% in March. Stock a...
Filed 2026-02-24. Core distribution 3-4% growth on track. Specialty/Tech accelerating (11.7% + 5.1% of sales). FY guidance raised to .88-.96 EPS (3-4% growth). KKR partnership announced with $200M+ op...
HSIC 10-K: Mature distribution leader with favorable demographics and cost-containment tailwinds. Core dental distribution under mix pressure; specialty products and technology segment growth accelera...